Table 2.

TERT SNP genotype and cancer risk

TERT rs401681OR (95% CI), P-het
Breast cancer (6,800 cases, 6,608 controls)Colorectal cancer (2,259 cases, 2,246 controls)Melanoma (782 cases, 999 controls)
CC1.00 reference1.00 reference1.00 reference
CT1.02 (0.94-1.10), 0.491.09 (0.96-1.25), 0.191.01 (0.79-1.29), 0.95
TT1.01 (0.92-1.12), 0.701.02 (0.86-1.21), 0.800.98 (0.70-1.37), 0.90
Per T allele1.01 (0.96-1.06)1.02 (0.94-1.11)0.99 (0.84-1.17)
P trend = 0.64P trend = 0.66P trend = 0.91

NOTE: Genotype frequencies in cases and controls were compared using a 2 df χ2 test for heterogeneity (P-het) and a 1 df Cochran-Armitage χ2 test for trend in risk by T allele dose (P trend). Genotype-specific risks were estimated as ORs with associated 95% CI using unconditional logistic regression. For each study, the deviation of genotype distribution in controls from Hardy-Weinberg equilibrium was assessed by a χ2 test with 1 df (data not shown).